Catalent to Present Scientific Innovations and Lead Drug Delivery Discussions at the Controlled Release Society Annual Meeting

Share Article

Catalent, the leading global provider of advanced delivery technologies, and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced a number of its drug delivery experts have been invited to present innovative scientific posters, and that Cornell Stamoran, Ph.D., founder of Catalent’s Applied Drug Delivery Institute, has been invited to chair multiple sessions at the upcoming Controlled Release Society (CRS) Annual Meeting and Exposition at the Palacio de Congresos, Valencia, Spain on July 21-24, 2019.

Catalent, the leading global provider of advanced delivery technologies, and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced a number of its drug delivery experts have been invited to present innovative scientific posters, and that Cornell Stamoran, Ph.D., founder of Catalent’s Applied Drug Delivery Institute, has been invited to chair multiple sessions at the upcoming Controlled Release Society (CRS) Annual Meeting and Exposition at the Palacio de Congresos, Valencia, Spain on July 21-24, 2019.

Catalent will present the following scientific posters:

  • “Scientific Networks: Beyond Scientists Engagement, A Key Asset to Boost Operational Excellence” presented by Nicolas Thurin, Ph.D., Global Analytical Science Manager;
  • “Modified Release Coated Soft Gelatin Capsules Dissolution and Physical Stability” presented by William Bell, Lead Scientist, Product Development;
  • “DOE-assisted Technology Transfer and Scale-up Approach of Manufacturing Complex Modified Release Multiparticulates in a Fluid Bed Platform” presented by Ariana Low, Ph.D., PD Principal Formulation Scientist;
  • “Solid Lipid and Hydrophilic Based Dosage Form Stabilization Through Curing and Addition of Low Hlb Surfactant(s)” presented by Monica Lazaro, Business Development Associate.

On Sunday, July 21 at 9 a.m., Dr. Stamoran will moderate the “Industry Technology Soapbox” session, before chairing an interactive session titled, “Industry: Problem Solving,” later in the day at 3:30 p.m. The latter session is designed to encourage potential drug delivery collaborations between industry and academic members, and participants will discuss pre-competitive opportunities and needs across the industry.

On Monday, July 22 at 10 a.m., Dr. Stamoran will moderate a session titled “Patient-Centered Aspects,” which will use examples and case studies to discuss current approaches to improving the design of treatments for patients. He will also chair the “Future Needs in Delivery Innovation” industry roundtables, taking place on Monday, July 22 at 5 p.m. and Tuesday, July 23 at 5 p.m.

Catalent, a founding corporate member of CRS, will also sponsor the Oral Delivery Focus Group Scientific session, taking place on Sunday, July 21 at 3:30 p.m., as well as the Oral Delivery Focus Group Membership Meeting, taking place on Tuesday, July 23 at 7 a.m. Both sessions will focus on small and large molecule drugs. They will introduce cutting edge science and technology being pioneered by CRS members and will feature industry and academic keynotes.

Dr. Stamoran leads Catalent’s strategic planning, market intelligence and government affairs efforts. He also founded and serves as Co-Chair of Catalent’s Applied Drug Delivery Institute (http://www.drugdeliveryinstitute.com). He has spent more than 30 years engaged with the health care industry, including more than 25 years in advanced drug and biologic delivery and outsourcing.

Full details of Catalent’s activities at the show can be found at https://www.catalent.com/index.php/news-events/events/CRS-Expo-2019.

To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR - richard(at)nepr(dot)agency

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling
Catalent
+44 7580 041073
Email >

Richard Kerns
Visit website